The Synthetic Routes of Veliparib dihydrochloride

Veliparib dihydrochloride is an anticancer drug used to treat various types of cancer, including breast cancer, ovarian cancer, and non-small cell lung cancer.
It works by inhibiting the activity of bromodomain and extraterminal domain (BET) proteins, which are involved in cell proliferation and survival.
The synthesis of veliparib dihydrochloride is a complex process that involves several steps, including the synthesis of the starting materials, the formation of the intermediate compounds, and the final synthesis of the drug itself.

The synthesis of veliparib dihydrochloride can be achieved through several different routes.
One of the most common methods is the synthesis of the starting material, known as 4-methylthio-2H-furo[2,3-d]pyrimidine-6-carboxylic acid.
This compound is synthesized by reacting 4-methylthiophene-2-carboxylic acid with 2H-furo[2,3-d]pyrimidin-6-one in the presence of a condensation agent such as dicyclohexylcarbodiimide (DCC).
The resulting product is then treated with a reducing agent such as hydrogen sulfide to convert it to the 6-carboxylic acid derivative.

Once the starting material has been synthesized, it can be converted to the intermediate compound known as 2-([4-((4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-2H-furo[2,3-d]pyrimidin-5-yl)-4,5,6,7-tetrahydro-5H-benzo[1,2-d]pyrimidin-4-one).
This compound is synthesized by treating the starting material with a compound known as 2-(difluoromethyl)-4-oxo-4H-furo[2,3-d]pyrimidin-5-carboxylic acid in the presence of a condensation agent such as hydroxybenzotriazole (HOBT) and a coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI).
The resulting product is then treated with a reducing agent such as hydrogenation to convert it to the desired intermediate compound.

The final step in the synthesis of veliparib dihydrochloride is the formation of the drug itself.
This is achieved by treating the intermediate compound with a compound known as 4-((4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-2H-furo[2,3-d]pyrimidin-5-yl)benzamide in the presence of a condensation agent such as HOBT and a coupling agent such as EDCI.
The resulting product is then treated with a reducing agent such as hydrogenation to remove the benzamide protecting group and form the final product, veliparib dihydrochloride.

The synthesis of veliparib dihydrochloride is a complex process that requires the use of a variety of chemical reagents and equipment.
It is typically carried out in a controlled environment, such as a laboratory or a manufacturing facility, by trained chemists or chemical engineers.
The process can be monitored and controlled to ensure the production of a high-quality final product.

In conclusion, the synthesis of veliparib dihydrochloride is a multi-step process that involves the synthesis of several intermediate compounds.
The process requires the use of a variety of chemical reagents and equipment, and is typically carried out in a controlled environment by trained chemists or chemical engineers.
The synthesis of this anticancer drug is an important step in the fight against cancer, and is an example of the power of chemical synthesis in the development of new and effective pharmaceuticals.